SOHO 2023 Eleventh Annual Meeting
Avatar

SOHO 2023: Incorporating Novel Agents in Frontline DLBCL

By SOHO 2023 Eleventh Annual Meeting FEATURING Laurie H. Sehn
By SOHO 2023 Eleventh Annual Meeting FEATURING Laurie H. Sehn
0 views
October 17, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Recommended

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
22:09
Scripps Health

New Updates in Frontline DLBCL

Feat. L. Nastoupil
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

04:04
Wojciech Jurczak

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

22:11
SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
08:01
Georg Lenz

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

34:36
MyCancerHaven

Frontline DLBCL Treatment Approaches

Feat. R. Vij, H. Cherng
15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
29:26
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in DLBCL and HL

Feat. J. Erika Haydu
16:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New Algorithm for 2L LBCL

Feat. J. Westin
04:29
Juan Pablo Alderuccio

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

30:07
Dipenkumar Modi

Current Management of DLBCL From Frontline to Relapsed Disease

33:48
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: B-Cell Lymphoma

Feat. L. Nastoupil
15:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…

Feat. J. Friedberg